Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

Similar documents
FIRSTQUARTER2018 RESULTSPRESENTATION

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

ACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

Tamsulosin Hydrochloride 0.4 mg Capsule

For personal use only

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX

RULES OF CONDUCT OF INSIDERS RESPECTING

PLEO-CMT Top-line Results. Presentation October 16, 2018

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Cavosonstat Phase 2 Trial Results. November 28 th, 2016

Investment in MGC Pharmaceuticals

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

Not an Offer for Securities

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease

These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017.

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer

Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape

Korean Airlines Q Results

AFFIN HOLDINGS BERHAD (Company No.: W) (Incorporated in Malaysia under the Companies Act, 2016) NOTICE TO SHAREHOLDERS IN RELATION TO THE

Investor presentation. Bioshares Biotech Summit July 2017

Dr. Francesco Amato (Italy)

TOBACCO INDUSTRY MONITORING TOOL

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

HILLENBRAND INDUSTRIES INC

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

(City, State, Zip Code)

Investor Presentation

SAGE-547 s mechanism of action is already addressed by other drugs that are commonly used to treat SRSE patients

CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees

Summary Statement of Financial Position (consolidated)

MDxHealth. Excellent Buy Opportunity. Research Note.

22nd Century Group, Inc. (XXII - $ Buy)

Infant Bacterial Therapeutics December 2018

Shareholder Presentation Annual Meeting 2018

PATENCY-1 Top-Line Results

Important Notices. BASIS CPD Points PN/50971/1516/g

Bodyweight Pilates Workout Calendar By: Sylvia Favela

FORM8-K HILLENBRAND,INC.

Connect with consumers for life. Introducing new MEG-3 Ultra and life sdha Ultra

NOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation

ASCAP RHYTHM & SOUL MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

on the advertising of medicinal products for human use

AR CS205 Clinical Pilot Study Topline Results

THE OPTICAL SOCIETY ONLINE JOURNALS SINGLE SITE LICENSE AGREEMENT

Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd

GENERAL TERMS AND CONDITIONS WCO PUBLICATIONS

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2019*

Developing Xanamem for Alzheimer s Dementia

4. The time limit, not less than thirty (30) calendar days, for requesting a Hearing in writing.

EKOS. Interventional Vascular 3 February, Imagine where we can go.

REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY

ASCAP COUNTRY MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

ASX Small to Mid Caps New York Conference. March 1, 2012

Morphine capsules retard

Advancing Pancreatic & Liver Cancer Treatment

Employment Contract. This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available)

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018

We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis

Clinical Review Report (Sample)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

Hello, Fundraiser! All the best, Julie Lowe Ronald McDonald House Charities of Greater Washington, DC

For personal use only

THE VILLAGE AT SAVANNAH QUARTERS

GI Dynamics, Inc. (ASX.GID) Focused on the Patient. Q Shareholder Update

Standards of Conduct for Transmission Providers

For personal use only OSPREY MEDICAL INC EXECUTIVE SUMMARY Q1 2015

USPSTF Draft Recommendations Investor Call. October 6, 2015

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018*

Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE

DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Acceptable Use Policy - Phone

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Analyst Report Written by Mark Bonacci, Chief Financial Analyst

Government Gazette REPUBLIC OF SOUTH AFRICA

Release & Waiver Synergy Studio

MDxHealth. AssureMDx leaves competition behind. Research Note.

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

How Well Are You Thinking?

NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

Diagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014

Presentation to 2019 JP Morgan Healthcare Conference

The Lipid Metabolism Company. Corporate Presentation March 2018

ORDINANCE NO

Annual Results 2017 & Business Update 13 April 2018

(English text signed by the State President) as amended by

Presentation of. Burgdorf, 1 st November 2012

MDxHealth. Strong outlook for Research Note.

ORDINANCE NO

Mental Toronto Hydro

Model 380B DNA Synthesizer Version 1.1

Transcription:

Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017

Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according to its nature, it is not provisional and which is not intended to give any forward-looking statements, estimates or future projections and should be read accordingly. The Information is publicly disclosed under the applicable rules and regulations and may be freely used under the condition that it shall remain unchanged. BCR renders no representation, warranty or undertaking, express or implied, with respect to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness thereof. Neither BCR nor any of its affiliates, subsidiaries, directors, representatives, employees and/or advisors shall not be held liable nor responsible for any direct or indirect damages whatsoever that may occur or that may arise from any use of the Information or otherwise arising in connection with this presentation or as a result of any use or manipulation, modification or alteration, update, revision or correction, whether intentional or not, of such information the Information. All data referred in this document must be reported to the document s date. Therefore, considering the nature and objective of the disclosure of the Information, BCR shall not be under any obligation to update said Information, nor shall it be under any obligation to make any prior announcement of any amendment or modification thereof its contents and therefore the Information may not be used in the future in connection with any offer (public or private) in relation to securities issued by BCR. Any decision to purchase, subscribe, exchange or otherwise trade any securities in any offering launched by BCR or on its behalf should be made solely on the basis of the information to be contained in the relevant prospectus, base prospectus or offering memorandum to be made available in due course in relation to any such offering in accordance with the applicable rules and regulations. The Information herein is provided for general purposes only and is not intended to constitute professional advice. Furthermore, the Information does not constitute or form part of and should not be construed as, an offer (public or private) to sell, issue, advertise, market, invite to subscribe, submit to investment gathering procedures or the solicitation of an offer (public or private) to buy or acquire securities of BCR or any of its affiliates in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. Use of data contained herein in its original format shall contain a quote as to the source of the information and/or a reference of where it was taken from. BRISA Concessão Rodoviária, S.A. Head-Office: Quinta da Torre da Aguilha, Edifício BRISA, São Domingos de Rana Share capital: EUR 75 000 000 Registered in the Commerce Registry Office of Cascais under register and corporate tax number 502790024 1Q 2017 Traffic update, 15 th May 2017 2

Traffic Update 1Q 2017 analysis Quarterly ADT * (Average Daily Traffic) Quarterly VKM growth 2016 2017 23 087 2016 1Q16 +9.9% 2016 +4.4% 16 308 15 617 18 002 17 392 2Q16 3Q16 4Q16 +5.1% +6.9% +6.6% +7.0% 1Q 2Q 3Q 4Q * ADT does not include negative leap year effect 2017 1Q 2017 1Q17 +3.3% Traffic mix 6.2% 93.8% LV/HV traffic growth (yoy) 12.4% 3.9% 1Q 2017 hampered by Easter effect (in 2016 Easter occurred on the 1Q, while in 2017 Easter was in April) and by leap year effect +3.3% Positive traffic performance continued during 1Q 2017 1Q 2017 Traffic update, 15 th May 2017 3

Traffic Update 1Q 2017 analysis VKM Growth Breakdown (cumulative) 2016 2017 1Q 16 2Q 16 3Q 16 4Q 16 1Q 17 ADT (organic) 6.7% 6.2% 6.0% 6.2% 6.5% Organic growth with a sound performance Calendar effect 2.0% 0.6% 0.8% 0.5% -2.3% 1Q17 hampered by Easter calendar effect Others 1.2% 0.5% 0.3% 0.3% -0.9% 1Q17 with a negative effect from leap year Total 9.9% 7.3% 7.1% 7.0% 3.3% 10% Breakdown of 1Q17 Traffic Growth (VKM) Organic growth Calendar effect Others 5% 0% 6.7% 6.2% 6.0% 6.2% 6.5% 6.5% -2.3% -0.9% 3.3% -5% 1Q16 2Q16 3Q16 4Q16 1Q17 Organic growth Calendar effect Others Total VKM Despite a steady organic traffic growth, 1Q 2017 was negatively affected by Easter and Leap year effects 1Q 2017 Traffic update, 15 th May 2017 4

Traffic Update 1Q 2017 analysis Average Daily Traffic * Oporto A14 A3 A4 65 978 27 517 26 923 10 769 17 490 4 418 19 196 5 589 17 684 2 649 3 845 16 308 A1 A1 A2 A3 A4 A5 A6 A9 A10 A12 A13 A14 BCR A10 A9 A5 Lisbon A12 A13 A2 A6 ADT Traffic Growth Rate * (YoY) 12.5% 7.6% 6.0% 5.6% 3.2% 3.5% 1.9% 7.4% 6.4% 1.4% 3.6% 4.4% A1 A2 A3 A4 A5 A6 A9 A10 A12 A13 A14 BCR Positive growth across all network * ADT does not include negative leap year effect 1Q 2017 Traffic update, 15 th May 2017 5